Shinohara N - Search Results

1

GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.

Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Among authors: shinohara n. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274 Free PMC article.

2

Gelsolin: a candidate for suppressor of human bladder cancer.

Tanaka M, Müllauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki N. Tanaka M, et al. Among authors: shinohara n. Cancer Res. 1995 Aug 1;55(15):3228-32. Cancer Res. 1995. PMID: 7614452

3

Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice.

Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N. Tanaka M, et al. Among authors: shinohara n. Cancer Gene Ther. 1999 Sep-Oct;6(5):482-7. doi: 10.1038/sj.cgt.7700073. Cancer Gene Ther. 1999. PMID: 10505859

4

Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.

Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takiguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N. Watanabe T, et al. Among authors: shinohara n. Cancer Lett. 2000 Feb 28;149(1-2):195-202. doi: 10.1016/s0304-3835(99)00359-6. Cancer Lett. 2000. PMID: 10737724

5

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.

Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF. Watanabe T, et al. Among authors: shinohara n. Cancer Gene Ther. 2000 Dec;7(12):1575-80. doi: 10.1038/sj.cgt.7700261. Cancer Gene Ther. 2000. PMID: 11228536

6

Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.

Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N. Watanabe T, et al. Among authors: shinohara n. Int J Cancer. 2001 Jun 1;92(5):712-7. doi: 10.1002/1097-0215(20010601)92:5<712::aid-ijc1242>3.0.co;2-z. Int J Cancer. 2001. PMID: 11340577 Free article.

7

Significance of COX-2 expression in human renal cell carcinoma cell lines.

Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T. Chen Q, et al. Among authors: shinohara n. Int J Cancer. 2004 Mar 1;108(6):825-32. doi: 10.1002/ijc.11646. Int J Cancer. 2004. PMID: 14712483 Free article.

8

Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer.

Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Suzuki S, et al. Among authors: shinohara n. Int J Urol. 2004 Jul;11(7):456-60. doi: 10.1111/j.1442-2042.2004.00841.x. Int J Urol. 2004. PMID: 15242352 Free article.

9

Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line.

Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K. Chen Q, et al. Among authors: shinohara n. J Urol. 2004 Dec;172(6 Pt 1):2153-7. doi: 10.1097/01.ju.0000143440.08760.3a. J Urol. 2004. PMID: 15538221

10

Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice.

Abe T, Tada M, Shinohara N, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi T, Nonomura K. Abe T, et al. Among authors: shinohara n. Int J Urol. 2006 Jan;13(1):47-57. doi: 10.1111/j.1442-2042.2006.01220.x. Int J Urol. 2006. PMID: 16448432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

823 results

Search Page